<DOC>
	<DOC>NCT00002019</DOC>
	<brief_summary>To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.</brief_summary>
	<brief_title>Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Cryptococcal</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Intravenous pentamidine for treatment of Pneumocystis carinii pneumonia (PCP) but not for prophylaxis. Patients must have the following: Meet the CDC criteria for diagnosis of AIDS. Confirmed episode of acute cryptococcal meningitis. Informed consent of the patient or guardian prior to entry. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans. History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B. Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study. Concurrent Medication: Excluded: Corticosteroids. Salicylates or other drugs known to interfere with prostaglandin synthesis except as specified in protocol. Zidovudine. Investigational agents. Interferon. Interleukin2 (IL2). Steroids. Isoprinosine. Intrathecal Amphotericin B. Intravenous Pentamidine PCP prophylaxis (only treatment). Patients with the following are excluded: Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans. History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B. Inability to obtain appropriate followup visits. Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study. Prior Medication: Excluded within 4 weeks of study entry: Amphotericin B. Excluded within 2 weeks of study entry: Any other experimental drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
	<keyword>Chemistry, Pharmaceutical</keyword>
</DOC>